Abstract
We report the use of low rugosity lactose, product of controlled crystallization of this carrier, in the formulation of terbutaline sulphate and beclomethasone dipropionate dry powder inhalers. The deposition patterns obtained with inhalation mixtures consisting of the modified lactose and each of the micronised drugs terbutaline sulphate and beclomethasone dipropionate have been used to assess the effect of the surface smoothing technique on aerosolised drug delivery. The ROTAHALER device and the Twin Impinger BP were used in the assessment. Drug deposited in the throat, stage 1 and stage 2 of the Twin Impinger BP was determined and used to assess the difference between commercial lactose and the modified lactose prepared. The respirable fraction obtained with inhalation mixtures containing the recrystallized lactose samples was higher compared with inhalation mixtures containing regular lactose BP.Keywords: Rotahaler device, terbutaline sulphate, beclomethasone dipropionate, inhalation mixtures, twin impinger BP, respirable fraction
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
